Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Chemotherapy-sensitive Lymphoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Chemotherapy-sensitive Lymphoma: 1 US clinical trial tracked, none currently recruiting.

Chemotherapy-sensitive Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Center for International Blood and Marrow Transplant Research, running 1 of these trials.

Enrollment posture brief

Registry condition chemotherapy-sensitive-lymphoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Chemotherapy-sensitive L (th…0%
Open-enrollment share among volume-matched conditions near Chemotherapy-sensitive Lymphoma

Chemotherapy-sensitive Lymphoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chemotherapy-sensitive Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chemotherapy-sensitive Lymphoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Chemotherapy-sensitive Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Infusion of non-T-cell depleted bone marrow on Day 0 Procedure
1 trials
Total Body Irradiation (TBI) 200cGy on Day -1 Radiation
1 trials
Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 Drug
1 trials
Busulfan Drug
1 trials
Fludarabine Drug
1 trials

US sites by state

Facility locations filed on Chemotherapy-sensitive Lymphoma trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Virginia 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Michigan 1 trials
Maryland 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chemotherapy-sensitive Lymphoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chemotherapy-sensitive Lymphoma condition card totals 1 registered trials; most-linked intervention Infusion of non-T-cell depleted bone marrow on Day 0; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.